| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Michael Robert A. | CHIEF EXECUTIVE OFFICER, Director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO | /s/ T.O. Odutayo, Attorney-in-Fact for Robert A. Michael | 20 Feb 2026 | 0001699914 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +33,833 | +25% | $0.000000 | 166,654 | 18 Feb 2026 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +12,030 | +7.2% | $0.000000 | 178,684 | 18 Feb 2026 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +14,452 | +8.1% | $0.000000 | 193,136 | 18 Feb 2026 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +22,124 | +11% | $0.000000 | 215,260 | 18 Feb 2026 | Direct | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to Buy) | Award | $0 | +81,251 | $0.000000 | 81,251 | 18 Feb 2026 | Common Stock | 81,251 | $230.04 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| F5 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029. |